![]() |
Technical Data |
|
V2110-07A |
Vascular Endothelial Growth Factor, Recombinant, Mouse (VEGF) |
2ug 10ug |
| Growth Factors, Cytokines | Storage: -20°CShipping: RT |
|
Vascular endothelial growth factor-A was originally isolated from tumor cells and referred to as Tumor Angiogenesis Factor or Vascular Permeability Factor. Although expressed at high levels in certain tumor-derived cells it is produced by a wide variety of cell types. In addition to stimulating vascular growth and vascular permeability it may play a role in stimulating Vasolidation via nitric oxide-dependent pathways. Alternative splicing of the mRNA for VEGF-A results in several isoforms of the protein being produced. Rat and bovine VEGF are one amino acid shorter than the human factor, and the bovine and human sequences show a homology of 95 percent. In contrast to other factors mitogenic for endothelial cells such as FGF-1, FGF-2 and PDGF, VEGF is synthesized as a precursor containing a typical hydrophobic secretory signal sequence of 26 amino acids. Glycosylation is not required for efficient secretion of VEGF. Recombinant Murine VEGF is a double, non-glycosylated, polypeptide chain containing 165 amino acids and having a molecular mass of 39kD. Sequence: The sequence of the first five N-terminal amino acids was determined and was found to be Met-Ala-Pro-Thr-Thr. Biological Activity: Determined by the dose-dependent stimulation of the proliferation of human umbilical vein endothelial cells (HUVEC) using a concentration range of 1.0-6.0ng/ml. Storage and Stability: Lyophilized powder may be stored at -20°C. Reconstitute to nominal volume by adding sterile dH2O, 0.1% BSA or HSA. Aliquot and store at -20°C. Reconstituted product is stable for 12 months at -20°C. For maximum recovery of product, centrifuge the original vial prior to removing the cap. Molecular Weight: 39.036kD |
Source: E. coli Purity: 95% by RP-HPLC, FPLC, or reducing/non-reducing SDS-PAGE Silver Stain. Chromatographically purified. Form: Supplied as a lyophilized powder. No additives. Reconstitute to with sterile dH2O, 0.1% HSA or BSA to 100ug/ml. Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological. |
|
1. Graells J, Vinyals A, Llorens A, Fabra A, J Invest Dermatol 2004 Dec;123(6):1151-61 2. Hiratsuka S, Kataoka Y, Nakamura K, Maru Y, Mol Cell Biol 2005 Jan;25(1):355-63 3. Eubank TD, Roberts R, Wang Y, Immunity 2004 Dec;21(6):831-42 4. Loureiro RM, Maharaj AS, Muller WJ, Biochem Biophys Res Commun 2005 Jan 14;326(2):455-65 5. Emoto M, Charnock-Jones DS, Ishiguro M, Hachisuga T, Gynecol Oncol 2004 Dec;95(3):474-82 6. Belo AV, Barcelos LS, Ferreira MA, Cancer Invest 2004;22(5):723-9.
|
||